International Clinical Trial: A Multicenter, Randomized, Open-Label, Blinded-Endpoint Trial of Tenecteplase versus Dual Antiplatelet Therapy in Mild Disabling Ischemic Stroke with Large Vessel Occlusion Beyond 4.5 Hours

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131721) titled 'A Multicenter, Randomized, Open-Label, Blinded-Endpoint Trial of Tenecteplase versus Dual Antiplatelet Therapy in Mild Disabling Ischemic Stroke with Large Vessel Occlusion Beyond 4.5 Hours' on Sept. 6.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: The First Affiliated Hospital of China Medical University

Condition: Acute mild disabling stroke with anterior circulation large vessel occlusion, onset 4.5-24 hours

Intervention: Control Group:Immediate standardized care

Recruitment Status: Not Recruiting

Phase: 3

Date of First Enrollment: 2026-09-06

Target Sample Size: Contro...